Innocoll is a biotherapeutics pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most important healthcare challenges.
We utilize our proprietary collagen-based technology platform to develop biodegradable and fully resorbable products. Our processes and technologies enable us to control the drug elution dynamics, texture, consistency, resorption time and other physical characteristics of the finished product. All of our native collagen products are manufactured at our certified, state-of-the-art, fully integrated plant in Saal, Germany.
Our current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Our lead product, XARACOLL® (bupivacaine HCl) Implant, was approved by the U.S. Food and Drug Administration in August 2020
We utilize our proprietary collagen-based technology platform to develop biodegradable and fully resorbable products. Our processes and technologies enable us to control the drug elution dynamics, texture, consistency, resorption time and other physical characteristics of the finished product. All of our native collagen products are manufactured at our certified, state-of-the-art, fully integrated plant in Saal, Germany.
Our current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Our lead product, XARACOLL® (bupivacaine HCl) Implant, was approved by the U.S. Food and Drug Administration in August 2020
Location: United States, Alabama, Satsuma
Employees: 51-200
Founded date: 1985
Investors 3
Mentions in press and media 1
| Date | Title | Description |
| 25.07.2017 | Term Sheet — Tuesday, July 25 | CRYPTO MANIA Hi, Term Sheet readers. My name is Robert Hackett, and I’m a reporter here are Fortune. You might remember me from this Q&A that appeared in Term Sheet a couple months ago. Paid Content Securing the enterprise without bound... |